Bruton’s tyrosine kinase (BTK) inhibitors, which are currently first-line treatments for chronic lymphocytic leukemia (16), represent an emerging class of compounds for the treatment of autoimmune diseases (17, 18). The gene discussed is BTK; the disease is autoimmune disease.